Mayo Clinic is a nonprofit organization committed to inspiring hope and contributing to health and well-being by providing the best care to every patient through integrated clinical practice, education and research.
We gifted Mayo Clinic with $50,000 to support the Rhabdomyosarcoma research trial of Dr. Allen-Rhoades. Rhabdomyosarcoma (RMS) is the most common malignant soft tissue tumor diagnosed in children and adolescents each year in the United States. In this trial, Allen-Rhoades' team will collect tumor samples as well as "next-generation sequencing" (NGS) to study what makes these tumors so hard to treat. By understanding the biology of these tumors, researchers will be able to design novel therapeutic treatments to increase the chance that children and adolescents diagnosed with high-risk Rhabodomyosarcoma will become long-term survivors.
Completion of this project will fill a gap of knowledge of high-risk RMS genomics and provide insight into future precision medicine approaches for pediatric cancers.
Years Given: 2021